Factors Affecting Graft Survival among Patients Receiving Kidneys from Live Donors: A Single-Center Experience

Table 3

Graft survival relative to posttransplantation variables.

	No. of; patients	5-year; survival %	95% CI		10-year; survival %	95% CI		P value; (log rank)
Induction therapy
No	1108	86.5	84.34	88.66	64.6	61.66	67.54	0.536
Yes	859	87.1	84.75	89.45	69.5	64.80	74.20
Primary immunosuppression
(i) Aza-based (dual therapy)	309	82.2	77.69	86.71	58.3	52.42	64.18	<0.001
(ii) CsA-based (dual therapy)	303	84.8	79.12	90.48	57.8	49.76	65.84
(iii) CsA-based (triple therapy)	988	86.9	84.74	89.06	66.5	63.36	69.64
(iv) Tacrolimus-based (triple therapy)	217	91.6	88.27	94.93	86.2	80.91	91.49
(v) Sirolimus-based therapy	85	88.9	82.04	95.76	—	—
Total steroid dose; (during first 3 months)
<5 gm	1158	89.3	87.34	91.26	70.3	66.77	73.83	<0.001
5–10 gm	601	85.0	82.06	87.94	64.8	60.68	68.92
>10 gm	208	77.9	72.02	83.78	46.9	39.65	54.15
No. of acute rejection episodes; (during first 3 months)
(i) No	708	94.2	92.44	95.96	82.1	78.18	86.02	<0.001
(ii) One	661	89.6	87.25	91.95	69.4	65.28	73.52
(iii) ≥2	598	75.8	72.27	79.33	47.5	43.19	51.81
Urological complications
(i) No	1816	87.0	85.43	88.57	65.9	63.35	68.45	0.449
(ii) Yes	151	83.6	77.52	89.68	61.4	51.99	70.81
Post-transplant hypertension
(i) Normotensive	758	86.2	83.46	88.94	75.7	71.58	79.82	<0.001
(ii) Sustained hypertension	809	88.0	85.65	90.45	65.9	62.18	69.62
(iii) Newly developed hypertension	400	85.7	82.17	89.23	56.0	50.71	61.29